Becker Capital Management Inc Lowers stake in Merck & Co. (MRK)

Merck & Co. (MRK) : Becker Capital Management Inc reduced its stake in Merck & Co. by 0.08% during the most recent quarter end. The investment management company now holds a total of 1,087,166 shares of Merck & Co. which is valued at $61.4 Million after selling 915 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on May 25, 2016.Merck & Co. makes up approximately 2.56% of Becker Capital Management Inc’s portfolio.

Other Hedge Funds, Including , 10-15 Associates reduced its stake in MRK by selling 190 shares or 0.15% in the most recent quarter. The Hedge Fund company now holds 129,032 shares of MRK which is valued at $7.3 Million. Merck & Co. makes up approx 2.22% of 10-15 Associates’s portfolio. Sio Capital Management sold out all of its stake in MRK during the most recent quarter. The investment firm sold 54,375 shares of MRK which is valued $3 Million.Homrich Berg boosted its stake in MRK in the latest quarter, The investment management firm added 1,189 additional shares and now holds a total of 28,538 shares of Merck & Co. which is valued at $1.5 Million. Merck & Co. makes up approx 0.15% of Homrich Berg’s portfolio.Salient Capital Advisors reduced its stake in MRK by selling 1,901 shares or 29.97% in the most recent quarter. The Hedge Fund company now holds 4,442 shares of MRK which is valued at $239,335. Merck & Co. makes up approx 0.01% of Salient Capital Advisors’s portfolio.Argent Trust Co reduced its stake in MRK by selling 1,172 shares or 3.66% in the most recent quarter. The Hedge Fund company now holds 30,870 shares of MRK which is valued at $1.7 Million. Merck & Co. makes up approx 0.81% of Argent Trust Co’s portfolio.

Merck & Co. opened for trading at $56.2 and hit $56.52 on the upside on Wednesday, eventually ending the session at $56.33, with a gain of 0.12% or 0.07 points. The heightened volatility saw the trading volume jump to 66,91,013 shares. Company has a market cap of $155,923 M.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Investors should note that on May 24, 2016, Merck & Co. announced a cash dividend of $0.4600. The company’s management has announced Jun 13, 2016 as the ex-dividend date and fixed the record date on Jun 15, 2016. The payable date has been fixed on Jul 8, 2016.

Many Wall Street Analysts have commented on Merck & Co.. Societe Generale Initiated Merck & Co. on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $80.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.